NCT00438776View on ClinicalTrials.gov

Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling

PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Pathological Gambling
Interventions
DRUG

olanzapine

2.5mg to 15mg daily

DRUG

sugar pill

matching placebo to olanzapine

Trial Locations (1)

45267-0559

University of Cincinnati Medical Center, Cincinnati

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

University of Cincinnati

OTHER

lead

Lindner Center of HOPE

OTHER

NCT00438776 - Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling | Biotech Hunter | Biotech Hunter